CN109400608A - 二氮杂螺[4，5]癸烷酒石酸类衍生物制备和应用 - Google Patents
二氮杂螺[4，5]癸烷酒石酸类衍生物制备和应用 Download PDFInfo
- Publication number
- CN109400608A CN109400608A CN201811537842.5A CN201811537842A CN109400608A CN 109400608 A CN109400608 A CN 109400608A CN 201811537842 A CN201811537842 A CN 201811537842A CN 109400608 A CN109400608 A CN 109400608A
- Authority
- CN
- China
- Prior art keywords
- compound
- diazaspiro
- oxo
- diaza spiro
- methylene chloride
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- -1 diaza spiro [4,5] decane tartaric acids derivatives Chemical class 0.000 title abstract description 17
- 150000001875 compounds Chemical class 0.000 claims abstract description 21
- 241000894006 Bacteria Species 0.000 claims abstract description 10
- 241000233866 Fungi Species 0.000 claims abstract description 7
- 239000003814 drug Substances 0.000 claims abstract description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical group ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 45
- 241000894007 species Species 0.000 claims description 12
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 8
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 6
- 241000191967 Staphylococcus aureus Species 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- 241000222122 Candida albicans Species 0.000 claims description 5
- 229940095731 candida albicans Drugs 0.000 claims description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 4
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 4
- 229940125898 compound 5 Drugs 0.000 claims description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 4
- 241001225321 Aspergillus fumigatus Species 0.000 claims description 3
- 201000007336 Cryptococcosis Diseases 0.000 claims description 3
- 241000221204 Cryptococcus neoformans Species 0.000 claims description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 3
- 241000588724 Escherichia coli Species 0.000 claims description 3
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 3
- 229940091771 aspergillus fumigatus Drugs 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 244000005700 microbiome Species 0.000 claims description 3
- 238000010189 synthetic method Methods 0.000 claims description 3
- 241000228197 Aspergillus flavus Species 0.000 claims description 2
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 claims description 2
- 229960003085 meticillin Drugs 0.000 claims description 2
- 150000003413 spiro compounds Chemical class 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 230000001775 anti-pathogenic effect Effects 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 abstract description 4
- 241000192125 Firmicutes Species 0.000 abstract description 2
- 239000003429 antifungal agent Substances 0.000 abstract description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 abstract 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 230000002924 anti-infective effect Effects 0.000 abstract 1
- 150000001555 benzenes Chemical class 0.000 abstract 1
- 230000004071 biological effect Effects 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 239000002994 raw material Substances 0.000 abstract 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 64
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 30
- DNSISZSEWVHGLH-UHFFFAOYSA-N butanamide Chemical compound CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 description 28
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 19
- 238000005160 1H NMR spectroscopy Methods 0.000 description 19
- 239000000843 powder Substances 0.000 description 18
- 239000011734 sodium Substances 0.000 description 10
- 125000003003 spiro group Chemical group 0.000 description 8
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 6
- 239000000243 solution Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- VIMMECPCYZXUCI-MIMFYIINSA-N (4s,6r)-6-[(1e)-4,4-bis(4-fluorophenyl)-3-(1-methyltetrazol-5-yl)buta-1,3-dienyl]-4-hydroxyoxan-2-one Chemical compound CN1N=NN=C1C(\C=C\[C@@H]1OC(=O)C[C@@H](O)C1)=C(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 VIMMECPCYZXUCI-MIMFYIINSA-N 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000000845 anti-microbial effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 3
- 229960004884 fluconazole Drugs 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- FANCTJAFZSYTIS-IQUVVAJASA-N (1r,3s,5z)-5-[(2e)-2-[(1r,3as,7ar)-7a-methyl-1-[(2r)-4-(phenylsulfonimidoyl)butan-2-yl]-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol Chemical compound C([C@@H](C)[C@@H]1[C@]2(CCCC(/[C@@H]2CC1)=C\C=C\1C([C@@H](O)C[C@H](O)C/1)=C)C)CS(=N)(=O)C1=CC=CC=C1 FANCTJAFZSYTIS-IQUVVAJASA-N 0.000 description 2
- LKSOZXDPRFHPOI-UWVGGRQHSA-N (4S,5S)-2,2-dimethyl-5-(phenylcarbamoyl)-1,3-dioxolane-4-carboxylic acid Chemical compound CC1(O[C@@H]([C@H](O1)C(=O)O)C(NC1=CC=CC=C1)=O)C LKSOZXDPRFHPOI-UWVGGRQHSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 229930182764 Polyoxin Natural products 0.000 description 2
- 241000588769 Proteus <enterobacteria> Species 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000003178 anti-diabetic effect Effects 0.000 description 2
- 230000001857 anti-mycotic effect Effects 0.000 description 2
- 239000003472 antidiabetic agent Substances 0.000 description 2
- 239000002543 antimycotic Substances 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical class ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- GVOISEJVFFIGQE-YCZSINBZSA-N n-[(1r,2s,5r)-5-[methyl(propan-2-yl)amino]-2-[(3s)-2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide Chemical compound CC(=O)N[C@@H]1C[C@H](N(C)C(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 GVOISEJVFFIGQE-YCZSINBZSA-N 0.000 description 2
- 229960001699 ofloxacin Drugs 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- YEBIHIICWDDQOL-YBHNRIQQSA-N polyoxin Polymers O[C@@H]1[C@H](O)[C@@H](C(C=O)N)O[C@H]1N1C(=O)NC(=O)C(C(O)=O)=C1 YEBIHIICWDDQOL-YBHNRIQQSA-N 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- HHIOFHJYOIVJJK-UHFFFAOYSA-N 2,8-diazaspiro[4.5]decan-1-one Chemical compound O=C1NCCC11CCNCC1 HHIOFHJYOIVJJK-UHFFFAOYSA-N 0.000 description 1
- ZRNSSRODJSSVEJ-UHFFFAOYSA-N 2-methylpentacosane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCC(C)C ZRNSSRODJSSVEJ-UHFFFAOYSA-N 0.000 description 1
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 241001337994 Cryptococcus <scale insect> Species 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 206010041925 Staphylococcal infections Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000000049 anti-anxiety effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 150000001923 cyclic compounds Chemical class 0.000 description 1
- 238000005906 dihydroxylation reaction Methods 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- IPZJQDSFZGZEOY-UHFFFAOYSA-N dimethylmethylene Chemical compound C[C]C IPZJQDSFZGZEOY-UHFFFAOYSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000033065 inborn errors of immunity Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- NBVXSUQYWXRMNV-UHFFFAOYSA-N monofluoromethane Natural products FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 238000011127 radiochemotherapy Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 239000002447 tumor necrosis factor alpha converting enzyme inhibitor Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明属医药领域，具体涉及1‑氧代‑2,8‑二氮杂螺[4.5]癸烷L‑酒石酸衍生物类化合物及其制备方法和应用，所述化合物的结构如通式1所示：式中R1为氢；R2为：苯或取代苯。经生物活性测试实验证明，部分化合物对革兰阳性菌、革兰阴性菌和真菌都有一定抑制活性，可用于制备抗细菌和/或抗真菌药物，并且制备原料简单，廉价易得，对抗感染方面的应用具有重要意义。
Description
技术领域
本发明属医药领域，具体涉及1-氧代-2,8-二氮杂螺[4.5]癸烷L-酒石酸衍生物类化合物的设计合成及其在抗微生物方面的应用。
背景技术
近些年，由于抗生素的滥用、肿瘤放化疗、器官移植抗排斥和艾滋病等原因造成机体免疫力低下，使得菌类感染的发病率与死亡率逐年上升，已严重威胁人类的健康，因此探索与合成一种新型抗菌类药物在国内外医学领域备受关注。
螺环结构是天然产物与药物化合物中常见的一种环状化合物，螺环化合物因其两环平面相互垂直的结构、杂环螺具备螺共轭、螺超共轭或异头效应等一般有机化合物不具备的特殊性质及其含有电负强的O，N等杂原子与其它分子之间能够形成的较大的分子间作用力等独特优势，被广泛应用于抗真菌、抗肿瘤、抗病毒、抗焦虑、抗糖尿病、消炎等医学领域。此外，以L-酒石酸作为linker的核苷糖类衍生物也具备较高几丁质合成酶抑制活性，同时L-酒石酸在TACE抑制剂，抗糖尿病等医学领域均表现出了优异的活性，这类化合物的研究文章可见：Cheminform, 2006, 62(5):779-828.；Bioorg. Med. Chem.Lett.2012, 22(11):3643-364；Bioorg. Med. Chem.Lett. 2010, 20(16):4895-4900；Bioorg. Med. Chem.Lett.2008, 18(18):4997-5001；Bioorg. Med. Chem.Lett.2010, 20(16):4895-4900。
本发明设计并合成了一类1-氧代-2,8-二氮杂螺[4. 5]癸烷L-酒石酸衍生物类化合物，以多抗霉素B、氟康唑、链霉素和左氧氟沙星为对照，测定了该类化合物在抗真菌、抗细菌方面的活性，拓展了此类化合物的应用范围。到目前为止，本发明所涉及的新型化合物在抗微生物活性方面还未见报道，所以可将其开发成新型的抗菌制剂，为人类的健康做出贡献。
发明内容
本发明的目的之一在于提供一种1-氧代-2,8-二氮杂螺[4.5]癸烷L-酒石酸衍生物类；本发明的目的之二在于提供1-氧代-2,8-二氮杂螺[4.5]癸烷L-酒石酸衍生物类的制备方法；本发明的目的之三在于提供所述的1-氧代-2,8-二氮杂螺[4.5]癸烷L-酒石酸衍生物类在制备抗细菌/抗真菌药物中的应用。
为达到上述目的，本发明提供如下技术方案：
1、本发明所述的1-氧代-2,8-二氮杂螺[4.5]癸烷L-酒石酸衍生物类结构如通式1所示：
其中R1为H，R2为Ph，4-ClC6H4，2-CH3OC6H4，2,4-ClC6H3，2-BrC6H4，4-FC6H4，2-CH3C6H4，3,5-F3CC6H3，4-CH3OC6H4，3,4-FC6H3，2-FC6H4，4-O2NC6H4，3-F3CC6H4，3-Cl-4-FC6H3，3-CH3OC6H4，4-BrC6H4，2- ClC6H4或2,4-FC6H3等等，上述物质是分别唯一对应一个结构式的具体化合物，具体地，通式1所示的1-氧代-2, 8-二氮杂螺[4.5]癸烷L-酒石酸衍生物类为下述化合物的任意一种。
上述1-氧代-2,8-二氮杂螺[4.5]癸烷L-酒石酸衍生物类的合成方法，按如下进行：
如Scheme1所示
具体地说，上述Scheme1 反应条件如下：
a. 化合物2与化合物3a经缩合，酯碱性条件下水解生成化合物4a。溶剂为二氯甲烷、三氯甲烷、四氢呋喃、二氧六环等，优选二氯甲烷；化合物2，3a，的摩尔比为1: 1.1~2，室温至50℃，反应4-8 h。
b. 化合物4a再与化合物5，经T3P缩合，最后脱羟基保护生成化合物1a，溶剂为二氯甲烷、三氯甲烷、四氢呋喃、二氧六环等，优选二氯甲烷；化合物5：4a摩尔比1: 1.1~2，优选二氯甲烷为溶剂，室温至50℃反应6-12 h。。
本领域普通技术人员均可按上述公开的制备方法制得相应的化合物。
上述1-氧代-2,8-二氮杂螺[4.5]癸烷L-酒石酸衍生物类在制备抗病原微生物药物中的应用。所述微生物为病原细菌或病原真菌，如大肠杆菌、金黄色葡萄球菌、耐甲氧西林金黄色葡萄球菌、枯草杆菌、变形杆菌、铜绿色假单胞菌；白色念珠菌、新型隐球菌、黄曲霉菌、烟曲霉菌等。
具体实施方式
为了加深对本发明的理解，下面将结合实施例对本发明作进一步详述，该实施例仅用于解释本发明，并不构成对本发明保护范围的限定，但本领域的技术人员根据本发明的上述内容作出的一些非本质的改进和调整均属于本发明的保护范围。
实施例1、（4S，5S）-2,2-二甲基-5-（苯基氨基甲酰基）-1,3-二氧戊环-4-羧酸（4a）的制备
依次称取保护的L-酒石酸【（4S，5S）-5-（乙氧基羰基）-2,2-二甲基-1,3-二氧戊环-4-羧酸】即化合物2（2.24 g，10.31 mmol）、1-羟基苯并三唑（1.39 g，10.31 mmol）、二甲基氨基吡啶（1.26 g，10.31 mmol）、N, N-二环己基碳二酰亚胺（2.34 g，11.34 mmol）加入干燥的二氯甲烷（50 ml）中，室温搅拌30 min。加入化合物3a（1.06 g，11.34 mmol），室温反应8h。抽滤，滤液依次用饱和的碳酸氢钠、稀盐酸（0.01 mol/L）和水洗剂，无水硫酸钠干燥，抽滤，真空浓缩得到粗产物2.3 g，将粗产物（2.1 g，7.16 mmol）溶于1, 4-二氧六环和水（42mL，1: 1v/v）的混合溶剂中，室温下滴加1 mol/L氢氧化钠溶液（7.2 mL，7.16 mmol），滴加完毕后再室温反应3 h，用二氯甲烷萃取（15 mL×2），水层用1mol/L稀盐酸调PH到2-3，水层用二氯甲烷萃取（15 mL×2），合并有机层，无水硫酸钠干燥，抽滤，真空浓缩，柱层析后即得到化合物4a（1.2 g），浅黄色油状液体，收率65.0%；1H NMR (600 MHz, CDCl3) δ 8.41 (s,1H,CONH), 7.58 (d, J = 7.9 Hz, 2H,Ph-2,6-H), 7.39 (t, J = 7.9 Hz, 2H,Ph-3,5-H), 7.21 (t, J=7.4 Hz, 1H,Ph-4-H), 4.79 (d, J=7.6 Hz, 1H,CH), 4.75 (d, J=7.6Hz, 1H,CH), 1.57 (d, J=2.9 Hz, 6H,C(CH3)2)。按相似的合成方法，可得化合物4b-4r。
实施例 2、（2S，3S）-2,3-二羟基-4-氧代-4-（1-氧代-2,8-二氮杂螺[4.5]癸烷-8-基）-N-苯基丁酰胺(1a)的制备
在25 mL 圆底烧瓶中加入化合物4a（0.68g，2.56mmol），二氯甲烷15 mL,三乙胺（0.47g，4.66mmol），丙基磷酸三环酸酐（2.96g，4.66mmol），室温搅拌20min后，加入2,8-二氮杂螺[4.5]癸-1-酮，即化合物5（0.36g，2.33 mmol），继续搅拌30 min后加热到45℃反应12h，冷却至室温，加入15mL饱和碳酸氢钠溶液，用二氯甲烷萃取（15 mL×2）, 合并有机层，无水硫酸钠干燥，抽滤，真空浓缩得到粗产物0.49g，将粗产物（0.49g，1.22mmol）溶于甲醇20mL和1mol/L稀盐酸（6.1mL）的混合溶剂中，50℃反应4h，冷却至室温，加水15 mL，用1mol/L氢氧化钠溶液调PH到7-8，二氯甲烷萃取（15 mL×2），合并有机层，无水硫酸钠干燥，抽滤，真空浓缩，柱层析得到化合物1a（0.21 g），白色粉末， 产率48.6%，熔点：106.3-107.5℃；1HNMR (600 MHz, MeOD) δ 7.62 (d, J=7.9 Hz, 2H,Ph-2,6-H), 7.33 (dd, J=10.8, 5.1Hz, 2H,Ph-3,5-H), 7.12 (t, J =7.4 Hz, 1H, Ph-4-H), 4.94 (d, J=5.4 Hz, 1H,OH),4.38 (d, J=11.6 Hz, 1H,OH), 4.35-4.27 (m, 1H,CH), 4.13-4.07 (m, 1H,CH), 3.40-3.30 (m, 4H,diazaspiro-7,9-H), 2.14 (t, J=6.9 Hz, 2H, diazaspiro-3-H), 1.90-1.76 (m, 2H, diazaspiro-6-H,), 1.60 -1.50 (m, 2H, diazaspiro-10-H), 1.34-1.27(m, 2H, diazaspiro-4-H).13C NMR (151 MHz, MeOD) δ 181.81(1C), 170.97(1C),170.20(1C) , 137.48(1C) , 128.44 (2C), 124.29(1C) , 120.19 (2C), 72.72(1C) ,69.82(1C) , 42.52(1C) , 41.85(1C) , 39.08(1C), 38.45(1C) , 32.24(1C), 31.29(2C).HRMS(ESI): calcd. for C18H23N3O5 [M+H]+ , 362.1710, found, 362.1716.
按相同合成步骤，可得化合物1b-1r。
（2S，3S）-N-（4-氯苯基）-2,3-二羟基-4-氧代-4-（1-氧代-2,8-二氮杂螺[4.5]癸-8-基）丁酰胺（1b）
产率52.4%；白色粉末；熔点：130.2-131.2℃；1H NMR (600 MHz, CDCl3) δ 8.89 (s,1H,CONH), 7.47 (t, J=6.9 Hz, 2H,Ph-2,6-H), 7.15 (t, J=8.9 Hz, 2H,Ph-3,5-H),6.52 (s, 1H,CONH), 4.96 (s, 1H,OH), 4.34 (s, 1H,OH), 4.21 (dd, J=26.8, 13.3Hz, 1H,CH), 4.00-3.87 (m, 1H,CH), 3.28-2.92 (m, 4H,diazaspiro-7,9-H), 2.24-1.72 (m, 6H,diazaspiro-3,6,10-H), 1.42-1.33 (m, 2H,diazaspiro-4-H).13C NMR(151 MHz, CDCl3) δ 180.23(1C), 169.16(1C), 168.97(1C), 134.96(1C), 128.43(1C), 127.87(2C), 120.12(2C), 71.42(1C), 68.25(1C), 41.33(1C), 40.81(1C),38.49(1C), 37.86(1C),31.40(2C),30.72(1C).HRMS(ESI): calcd. for C18H22ClN3O5[M+H]+, 396.1321, found,396.1325.
（2S，3S）-2,3-二羟基-N-（2-甲氧基苯基）-4-氧代-4-（1-氧代-2,8-二氮杂螺[4.5]癸-8-基）丁酰胺 (1c)
产率46.9%；白色粉末；熔点：124.9-125.8℃；1H NMR (600 MHz, CDCl3) δ 9.25 (s,1H,CONH), 8.34-8.30 (m, 1H,Ph-6-H), 7.00-6.96 (m, 1H,Ph-4-H), 6.87 (dt, J=11.9, 6.1 Hz, 1H,Ph-3-H), 6.80 (t, J=6.8 Hz, 1H,Ph-5-H), 6.53 (s, 1H,CONH),4.97 (s, 1H,OH), 4.32 (s, 1H,OH), 4.24-4.13 (m, 1H,CH), 4.02-3.92 (m, 1H,CH),3.78 (s, 3H,Ph-OCH3), 3.30- 3.00 (m, 6H, diazaspiro-3,7,9-H), 1.96-1.71 (m,4H, diazaspiro-6,10-H), 1.40 (t, J=20.1 Hz, 2H, diazaspiro-4-H).13C NMR (151MHz, CDCl3) δ 180.17(1C), 169.26(1C), 168.75(1C), 147.51(1C), 126.03(1C),123.22(1C), 119.89(1C), 118.67(1C), 109.23(1C), 71.54(1C), 68.00(1C), 54.82(1C), 41.19(1C), 40.84(1C), 38.39(1C), 37.80(1C), 31.64(2C), 30.83(1C). HRMS(ESI): calcd. for C19H25N3O6 [M+Na]+, 414.1636, found,414.1638.
（2S，3S）-N-（2,4-二氯苯基）-2,3-二羟基-4-氧代-4-（1-氧代-2,8-二氮杂螺[4.5]癸-8-基）丁酰胺 (1d)
产率60.1%；白色粉末；熔点：112.5-113.2℃；1H NMR (600 MHz, CDCl3) δ 9.18 (s,1H,CONH), 8.32 (d, J=8.8 Hz, 1H,Ph-6-H), 7.31 (s, 1H,Ph-3-H), 7.17 (d, J=8.3Hz, 1H,Ph-5-H), 6.16 (s, 1H,CONH), 4.93 (s, 1H,OH), 4.35 (d, J=7.8 Hz, 1H,OH), 4.18 (dd, J=53.4, 13.1 Hz, 1H,CH), 4.06=3.94 (m, 1H,CH), 3.37-3.08 (m,4H,diazaspiro-7,9-H), 2.08=1.56 (m, 6H,diazaspiro-3,6,10-H), 1.51-1.40 (m, 2Hdiazaspiro-4-H,).13C NMR (151 MHz, CDCl3) δ 179.93(1C) , 169.01(1C) , 168.77(1C) , 131.88(1C), 128.47(1C), 127.87(1C), 126.78(1C), 122.96(1C), 120.97(1C), 71.49(1C) , 67.82(1C), 41.28(1C), 40.90(1C), 38.45(1C), 37.73(1C), 31.77(2C), 30.99(1C).HRMS(ESI)：calcd. for C18H21Cl2N3O5 [M+H]+ , 430.0931, found,430.0937.
（2S，3S）-N-（3-溴苯基）-2,3-二羟基-4-氧代-4-（1-氧代-2,8-二氮杂螺[4.5]癸-8-基）丁酰胺 (1e)
产率56.2%；白色粉末；熔点：126.8-128.3℃；1H NMR (600 MHz, CDCl3) δ 8.92 (s,1H,CONH), 7.83 (d, J = 11.9 Hz, 1H,Ph-2-H), 7.39 (t, J = 5.8 Hz, 1H,Ph-4-H),7.13 (t, J=8.4 Hz, 1H,Ph-5-H), 7.06 (q, J=7.8 Hz, 1H,Ph-6-H), 6.54 (s, 1H,CONH), 4.94 (dd, J=23.2, 6.8 Hz, 1H,OH), 4.36-4.30 (m, 1H,OH), 4.26-4.15 (m,1H,CH), 4.00-3.87 (m, 1H,CH), 3.26-2.93 (m, 4H,diazaspiro-7,9-H), 2.15 (s,2H,diazaspiro-3-H), 1.97-1.71 (m, 4H, diazaspiro-6,10-H), 1.37 (dd, J=16.8,8.5 Hz, 2H, diazaspiro-4-H). 13C NMR (151 MHz, CDCl3) δ 180.23, 169.16,168.93, 137.66, 129.18, 126.39, 121.77, 121.49, 117.36, 71.47, 68.27, 41.32,40.98, 40.82, 38.50 , 37.87, 31.43, 30.75.13C NMR (151 MHz, CDCl3) δ 180.23(1C), 169.16(1C), 168.93(1C), 137.66(1C), 129.18(1C), 126.39(1C), 121.77(1C),121.49(1C), 117.36(1C), 71.67(1C), 68.27(1C), 41.32(1C), 40.98(1C), 40.82(1C), 38.50(1C), 37.87(1C), 31.43(1C), 30.75(1C).HRMS(ESI): calcd. forC18H22BrN3O5 [M+Na]+, 462.0635, found,462.0632.
（2S，3S）-N-（4-氟苯基）-2,3-二羟基-4-氧代-4-（1-氧代-2,8-二氮杂螺[4.5]癸-8-基）丁酰胺 (1f)
产率47.8%；白色粉末；熔点：120.3-121.1℃；1H NMR (600 MHz, CDCl3) δ 8.78 (s,1H,CONH), 7.50-7.45 (m, 2H,Ph-2,6-H), 6.89 (t, J=8.0 Hz, 2H,PH-3,5-H), 6.39(s, 1H), 4.94 (s, 1H,OH), 4.33 (s, 1H,OH), 4.17 (d, J=13.4 Hz, 1H,CH), 3.93(d, J=13.8 Hz, 1H,CH), 3.34-2.97 (m, 5H,diazaspiro-3,7,9-H),2.00-1.73 (m, 5H,diazaspiro-3,6,10-H), 1.39 (d, J=13.5 Hz, 2H, diazaspiro-4-H).13C NMR (151MHz, CDCl3) δ 180.20(1C), 169.13(1C), 168.89(1C), 157.76(1C), 132.41(1C),120.72(2C), 114.59(1C), 114.44(1C), 71.38(1C), 68.17(1C), 41.33(1C), 40.91(1C), 38.51(1C), 37.82(1C), 31.56(2C), 30.85(1C).HRMS(ESI): calcd. forC18H22FN3O5 [M+Na]+ , 402.1436, found,402.1438.
（2S，3S）-2,3-二羟基-4-氧代-4-（1-氧代-2,8-二氮杂螺[4.5]癸烷-8-基）-N-（邻甲苯基）丁酰胺 (1g)
产率57.5%；白色粉末；熔点：115.4-116.5℃；1H NMR (600 MHz, CDCl3) δ 8.68 (s,1H,CONH), 7.94-7.90 (m, 1H), 7.17 (dd, J = 10.7, 6.1 Hz, 2H), 7.06 (q, J= 7.0Hz, 1H), 6.65 (s, 1H,CONH), 5.00 (s, 1H,OH), 4.43 (s, 1H,OH), 4.27 (dd, J=28.5, 13.2 Hz, 1H,CH), 4.03 (dd, J=33.9, 13.3 Hz, 1H,CH), 3.36-3.06 (m, 5H,diazaspiro-3,7,9-H), 2.27 (s, 3H,Ph-CH3), 2.04-1.76 (m, 5H, diazaspiro-3,6,10-H), 1.46 (dd, J=27.2, 14.0 Hz, 2H, diazaspiro-4-H).13C NMR (151 MHz, CDCl3)δ 181.22(1C), 170.17(1C), 169.87(1C), 135.17(1C), 130.44(1C), 129.03(1C),126.62(1C), 125.15 (1C), 122.28(1C), 72.48(1C), 69.06(1C), 42.27(1C), 41.85(1C), 39.40(1C), 38.83(1C), 32.54(2C), 31.87(1C), 17.53(1C).HRMS(ESI): calcd.for C19H25N3O5 [M+Na]+ , 398.1686, found, 398.1684.
（2S，3S）-N-（3,5-双（三氟甲基）苯基）-2,3-二羟基-4-氧代-4-（1-氧代-2,8-二氮杂螺[4.5]癸烷-8-基）丁丁酰胺 (1h)
产率62.4%；白色粉末；熔点：127.8-129.2℃；1H NMR (600 MHz, MeOD) δ 8.36 (s,2H,Ph-2,6-H), 7.66 (s, 1H,Ph-4-H), 4.95 (d, J=9.4 Hz, 1H,OH), 4.45 (d, J=11.8Hz, 1H,OH), 4.34 (dd, J=32.7, 12.6 Hz, 1H,CH), 4.12 (dd, J=25.2, 10.2 Hz, 1H,CH), 3.37 (dd, J=43.6, 23.8 Hz, 5H,diazaspiro-3,7,9-H), 2.20-1.75 (m, 5Hdiazaspiro-3,6,10-H), 1.57 (dd, J=34.4, 19.0 Hz, 2H, diazaspiro-4-H).13C NMR(151 MHz, MeOD) δ 181.83(1C), 171.98(1C), 169.94(1C), 139.83(1C), 131.91(1C),131.69 (1C), 124.22(1C), 122.42(1C), 119.77(2C), 116.66(1C), 72.78(1C), 69.98(1C), 42.53(1C), 41.78(1C), 39.11(1C), 38.45(1C), 32.27(1C), 31.45(2C).HRMS(ESI)：calcd. for C20H21F6N3O5 [M+H]+ ,498.1458,found,498.1458.
（2S，3S）-2,3-二羟基-N-（4-甲氧基苯基）-4-氧代-4-（1-氧代-2,8-二氮杂螺[4.5]癸-8-基）丁酰胺 (1i)
产率54.3%；白色粉末；熔点：114.4-115.5℃；1H NMR (600 MHz, CDCl3) δ 8.69 (s,1H,CONH), 7.42 (t, J= 8.1 Hz, 2H,PH-2,6-H), 6.75 (d, J=7.7 Hz, 2H,3,5-H),6.50 (s, 1H,CONH), 4.94 (s, 1H,OH), 4.31 (s, 1H,OH), 4.19 (dd, J=34.4, 12.8Hz, 1H,CH), 3.96 (dd, J=44.5, 13.2 Hz, 1H,CH), 3.69 (s,3H,Ph-OCH3), 3.53-2.95(m, 6H,diazaspiro-3,7,9-H), 1.96-1.71 (m, 4H,diazaspiro-6,10-H), 1.39 (s, 2H,diazaspiro-4-H).13C NMR (151 MHz, CDCl3) δ 180.22 (1C), 169.23(1C), 168.65(1C), 155.60(1C), 129.55(1C), 120.63(2C), 113.13(2C), 71.34(1C), 68.11(1C),54.48(1C), 41.26(1C), 40.84(1C), 38.45(1C), 37.83(1C), 31.55(2C), 30.85(1C).HRMS(ESI)：calcd. for C19H25N3O6 [M+H]+ ,392.1816,found,392.1816.
（2S，3S）-N-（3,4-二氟苯基）-2,3-二羟基-4-氧代-4-（1-氧代-2,8-二氮杂螺[4.5]癸-8-基）丁酰胺 (1j)
产率45.8%；白色粉末；熔点：112.5-113.5℃；1H NMR (600 MHz, CDCl3) δ 8.79 (s,1H,CONH), 7.62 (d, J=8.2 Hz, 1H,PH-2-H), 7.09 (s, 1H,Ph-5-H), 7.04-6.95 (m,1H,Ph-6-H), 6.28 (s, 1H,CONH), 4.94 (s, 1H,OH), 4.33 (s, 1H,OH), 4.21 (dd, J=34.5, 13.4 Hz, 1H,CH), 3.95 (d, J=12.4 Hz, 1H,CH), 3.35-2.97 (m, 6H,diazaspiro-3,7,9-H), 2.01 (d, J=17.9 Hz, 2H, diazaspiro-6-H), 1.94-1.75 (m,2H, diazaspiro-10-H), 1.44 (s, 2H, diazaspiro-4-H).13C NMR (151 MHz, CDCl3)δ180.01(1C), 169.12(1C), 168.90(1C), 141.22(1C), 133.36(1C), 122.98(1C),116.19(1C),114.60(1C), 108.68(1C), 71.18(1C), 68.041(1C), 41.33(1C), 40.86(1C), 38.56(1C), 37.78(1C), 31.42(2C), 30.87(1C).HRMS(ESI):calcd.forC18H21F2N3O5 [M+H]+, 398.1522, found,398.1522.
（2S，3S）-N-（2-氟苯基）-2,3-二羟基-4-氧代-4-（1-氧代-2,8-二氮杂螺[4.5]癸-8-基）丁酰胺 (1k)
产率55.3%；白色粉末；熔点：108.7-120.3℃；1H NMR (600 MHz, CDCl3) δ 8.91 (s,1H,CONH), 8.29-8.24 (m, 1H,PH-6-H), 7.07-6.96 (m, 3H,Ph-3,4,5-H), 6.36 (s,1H,CONH), 4.95 (d, J=5.4 Hz, 1H,OH), 4.35 (s, 1H,OH), 4.26-4.13 (m, 1H,CH),4.03-3.93 (m, 1H,CH), 3.33-3.04 (m, 4H,diazaspiro-7,9-H), 2.02-1.96 (m, 2H,diazaspiro-3-H), 1.95-1.78 (m, 4H,diazaspiro-6,10-H), 1.43 (t, J=14.9 Hz, 2H,diazaspiro-4-H).13C NMR (151 MHz, CDCl3) δ 180.14(1C), 169.01(1C), 168.79(1C),151.72(1C), 124.71(1C), 123.79(1C), 123.47(1C), 120.59(1C), 114.03(1C), 71.43(1C), 67.96(1C), 41.25(1C), 40.87(1C), 38.42(1C), 37.79(1C), 31.69(2C), 30.83(1C). HRMS(ESI): calcd. for C18H22FN3O5[M+H]+ , 380.1616, found, 380.1617.
（2S，3S）-2,3-二羟基-N-（4-硝基苯基）-4-氧代-4-（1-氧代-2,8-二氮杂螺[4.5]癸-8-基）丁酰胺 (1l)
产率49.7%；白色粉末；熔点：111.8-113.0℃；1H NMR (600 MHz, MeOD) δ 8.24-8.19(m, 2H,Ph-2,6-H), 7.93 (d, J=7.1 Hz, 2H,Ph-3,5-H), 4.94 (s, 1H,OH), 4.43 (s,1H,OH), 4.39-4.27 (m, 1H,CH), 4.11 (dd, J=28.3, 13.5 Hz, 1H,CH), 3.45-3.28(m, 4H, diazaspiro-7,9-H), 2.17 (dd, J=15.4, 8.8 Hz, 2H,diazaspiro-3-H),1.93-1.75 (m, 2H,diazaspiro-6-H), 1.56 (dd, J=32.9, 16.5 Hz, 2H,diazaspiro-10-H), 1.37-1.25 (m, 2H,diazaspiro-4-H).13C NMR (151 MHz, MeOD) δ 181.81(1C),171.67(1C), 170.02(1C), 143.73(1C), 143.63(1C), 124.27(2C), 119.53(2C), 72.88(1C), 69.97(1C), 42.51(1C), 41.78(1C), 39.09(1C), 38.45(1C), 32.27(1C), 31.46(2C).HRMS(ESI): calcd. for C18H22N4O7 [M+Na]+ ,429.1381,found,429.1400.
（2S，3S）-2,3-二羟基-4-氧代-4-（1-氧代-2,8-二氮杂螺[4.5]癸烷-8-基）-N-（3-（三氟甲基）苯基）丁酰胺 (1m)
产率56.3%；白色粉末；熔点：137.2-138.8℃；1H NMR (600 MHz, CDCl3) δ 9.09 (s,1H,CONH), 7.93 (d, J=15.1 Hz, 1H,Ph-2-H), 7.63 (d, J=7.6 Hz, 1H,PH-6-H), 7.27(t, J=8.2 Hz, 1H,Ph-5-H), 7.23-7.19 (m, 1H,Ph-4-H), 6.53 (s, 1H,CONH), 4.98(s, 1H,OH), 4.37 (s, 1H,OH), 4.26-4.15 (m, 1H,CH), 3.95 (dd, J=48.0, 13.1 Hz,1H,CH), 3.30-2.88 (m, 4H, diazaspiro-7,9-H), 2.40-1.70 (m, 6H, diazaspiro-3,6,10-H), 1.41 (dd, J=49.4, 15.3 Hz, 2H, diazaspiro-4-H).13C NMR (151 MHz,CDCl3)δ 180.34(1C), 169.37(1C), 168.91(1C), 136.92(1C), 130.25(1C), 128.36(1C), 122.00(1C), 121.83(1C), 119.91(1C), 115.52(1C), 71.72(1C), 68.36(1C),41.34(1C), 41.09(1C), 38.52(1C), 37.88(1C), 31.40(2C), 30.69(1C).HRMS(ESI):calcd. for C19H22F3N3O5 [M+Na]+ , 452.1404,found,452.1406.
（2S，3S）-N-（3-氯-4-氟苯基）-2,3-二羟基-4-氧代-4-（1-氧代-2,8-二氮杂螺[4.5]癸-8-基）丁酰胺(1n)
产率63.7%；白色粉末；熔点： 128.5-129.4℃；1H NMR (600 MHz, CDCl3) δ 8.94 (s,1H,CONH), 7.76-7.70 (m, 1H,Ph-2-H), 7.33-7.28 (m, 1H,Ph-5-H), 6.95 (q, J =9.2Hz, 1H,Ph-6-H), 6.51 (s, 1H,CONH), 4.94 (dd, J=24.5, 7.2 Hz, 1H,OH), 4.33(dd, J=21.6, 5.4 Hz, 1H,OH), 4.25-4.17 (m, 1H,CH), 4.02-3.88 (m, 1H,CH),3.30-2.94 (m, 4H,diazaspiro-7,9-H), 2.13 (s, 2H,diazaspiro-3-H), 1.99 (d, J=7.1 Hz, 2H,diazaspiro-6-H), 1.91-1.73 (m, 2H,diazaspiro-10-H), 1.45-1.35 (m,2H,diazaspiro-4-H).13C NMR (151 MHz, CDCl3) δ 180.17(1C), 168.99(1C), 168.90(1C), 154.64(1C), 133.04(1C), 120.98(1C), 119.98(1C), 118.54(1C), 115.52(1C),71.57(1C), 68.26(1C), 41.35(1C), 40.94(1C), 38.52(1C), 37.85(1C), 31.51(2C),30.77(1C).HRMS(ESI)：calcd. for C18H21ClFN3O5[M+H]+ , 414.1227 found, 414.1226.
（2S，3S）-2,3-二羟基-N-（3-甲氧基苯基）-4-氧代-4-（1-氧代-2,8-二氮杂螺[4.5]癸-8-基）丁酰胺 (1o)
产率47.5%；白色粉末；熔点：118.6-120.0℃；1H NMR (600 MHz, CDCl3) δ 8.90 (s,1H,CONH), 7.36 (d, J=11.7 Hz, 1H,Ph-2-H), 7.19 (td, J=8.1, 4.1 Hz, 1H,Ph-5-H), 7.09 (t, J=8.6 Hz, 1H,Ph-6-H), 6.65 (d, J=6.0 Hz, 1H,Ph-4-H), 6.63 (s,1H,CONH), 5.04 (s, 1H,OH), 4.41 (s, 1H,OH), 4.32-4.23 (m, 1H,CH), 3.99 (d, J=13.8 Hz, 1H,CH), 3.78 (s, 3H,Ph-OCH3), 3.34-3.02 (m, 4H,diazaspiro-7,9-H),2.40 (s, 2H,diazaspiro-3-H), 2.03-1.79 (m, 4H,diazaspiro-6,10-H), 1.46 (t, J=12.4 Hz, 2H,diazaspiro-4-H).13C NMR (151 MHz, CDCl3) δ 181.22(1C), 170.08(1C),169.93(1C), 160.09(1C), 138.49(1C), 129.57(1C), 112.14(1C), 110.54(1C),105.53(1C), 72.42(1C), 69.14(1C), 55.29(1C), 42.25(1C), 41.94(1C), 39.45(1C),38.82(1C), 32.43(2C), 31.75(1C).HRMS(ESI):calcd. for C19H25N3O6 [M+Na]+ ,414.1636,found,414.1635.
（2S，3S）-N-（4-溴苯基）-2,3-二羟基-4-氧代-4-（1-氧代-2,8-二氮杂螺[4.5]癸-8-基）丁酰胺 (1p)
产率54.8%；白色粉末；熔点： 122.8-123.6℃；1H NMR (600 MHz, CDCl3) δ 8.88 (s,1H,CONH), 7.41 (t, J=7.3 Hz, 2H,PH-2,6-H), 7.30 (t, J=9.2 Hz, 2H,Ph-3,5-H),6.48 (s, 1H,CONH), 4.95 (s, 1H,OH), 4.33 (s, 1H,OH), 4.25-4.17 (m, 1H,CH),3.90 (d, J=13.9 Hz, 1H,CH), 3.32-2.85 (m, 6H, diazaspiro-3,7,9-H), 1.96-1.70(m, 4H, diazaspiro-6,10-H), 1.37 (dd, J=18.2, 8.1 Hz, 2H,diazaspiro-4-H). 13CNMR (151 MHz, CDCl3) δ 180.24(1C), 169.01(1C), 168.95(1C), 135.46(1C), 130.83(2C), 120.46(2C), 116.09(1C), 71.44(1C), 68.26(1C), 41.34(1C), 41.04(1C),38.50(1C), 37.87(1C), 31.41(2C), 30.71(1C).HRMS(ESI):calcd. for C18H22BrN3O5 [M+Na]+ , 462.0635,found,462.0638.
（2S，3S）-N-（2-氯苯基）-2,3-二羟基-4-氧代-4-（1-氧代-2,8-二氮杂螺[4.5]癸-8-基）丁酰胺 (1q)
产率50.7%；白色粉末；熔点： 125.4-126.5℃；1H NMR (600 MHz, CDCl3) δ 9.24 (s,1H,CONH), 8.35 (dd, J=8.2, 3.0 Hz, 1H,Ph-6-H), 7.31-7.28 (m, 1H,Ph-3-H),7.20-7.17 (m, 1H,Ph-5-H), 6.98 (q, J=7.1 Hz, 1H,Ph-4-H), 6.38 (s, 1H,CONH),4.97-4.90 (m, 1H,OH), 4.36 (d, J=5.9 Hz, 1H,OH), 4.24-4.13 (m, 1H,CH), 4.06-3.93 (m, 1H,CH), 3.34-3.04 (m, 4H, diazaspiro-7,9-H), 2.02-1.75 (m, 6H,diazaspiro-4,6,10-H), 1.44 (dt, J = 20.2, 10.6 Hz, 2H, diazaspiro-4-H).13C NMR(151 MHz, CDCl3) δ 180.11(1C), 169.12(1C), 169.02(1C), 133.12(1C), 128.15(1C), 126.60(1C), 123.95(1C), 122.42(1C), 120.32(1C), 71.56(1C), 67.93(1C),41.26(1C), 40.89(1C), 38.44(1C), 37.78(1C), 31.70(2C), 30.93(1C).C18H22ClN3O5.HRMS: calcd. for C18H22ClN3O5 [M+Na]+, 418.1140, found, 418.1137.
（2S，3S）-N-（2,4-二氟苯基）-2,3-二羟基-4-氧代-4-（1-氧代-2,8-二氮杂螺[4.5]癸-8-基）丁酰胺 (1r)
产率46.4%；白色粉末；熔点：113.9-115.5℃；1H NMR (600 MHz, CDCl3) δ 8.80 (s,1H,CONH), 8.22-8.16 (m, 1H,Ph-3-H), 6.79 (s, 2H,Ph-5,6-H), 6.38 (d, J=9.0 Hz,1H,CONH), 4.95-4.88 (m, 1H,OH), 4.35 (s, 1H,OH), 4.20 (dd, J=43.6, 10.3 Hz,1H,CH), 4.07-3.92 (m, 1H,CH), 3.34-3.03 (m, 4H, diazaspiro-7,9-H), 2.06-1.75(m, 6H, diazaspiro-3,6,10-H), 1.49-1.38 (m, 2H,diazaspiro-4-H).13C NMR (151MHz, CDCl3) δ 180.16(1C), 169.11(1C), 168.79(1C), 156.91(1C), 151.10(1C).121.72(1C), 121.12(1C), 110.88(1C), 102.84(1C), 71.36(1C), 67.98(1C), 41.31(1C), 40.88(1C), 38.47(1C), 37.81(1C), 31.68 (2C), 30.86(1C).HRMS: calcd. forC18H21F2N3O5 [M+Na]+, 420.1341, found, 420.1344.
实施例3、1-氧代-2,8-二氮杂螺[4.5]癸烷L-酒石酸衍生物类的体外抗微生物活性
采用符合美国国家委员会制定的临床实验标准（Clinical and LaboratoryStandards Institute, CLSI）的96孔微量稀释法，检查实施例4制得的1-氧代-2,8-二氮杂螺[4.5]癸烷L-酒石酸衍生物类对革兰氏阳性菌（耐甲氧西林金黄色葡萄球菌（MRSA N315）、金黄色葡萄球菌（ATCC 25923）、枯草杆菌（ATCC 6633））、革兰氏阴性菌（大肠杆菌（JM109）、铜绿假单胞菌（ATCC 9027）、变形杆菌（ATCC 8427））和真菌（白色念珠菌（ATCC76615）、烟曲霉菌（GIMCC 3.19）、白色念珠菌（ATCC 90023）、黄曲霉菌（ATCC 16870）、新型隐球菌（ATCC 32719））的最低抑制浓度（MIC），将待测化合物用少量二甲亚砜溶解，用灭菌水制成溶液备用，将96孔板，西林瓶，枪头等物品高压灭菌，用移液枪移取稀释好的菌液溶液100uL到96孔板中，用链霉素，左氧氟沙星；氟康唑和多抗霉素 B作为参比对照。细菌，真菌在37℃培养24h，观察现象。结果见表1、表2。
由表可以看出，本发明实施例2制得的化合物1a-1r，对所测试的细菌和真菌均表现出一定的抑制作用，其中对真菌的抑制作用优于细菌的，特别地，3,5-二双三氟甲基取代的1h分别对白色念珠菌（ATCC 76615）和新型隐球菌表现出较高的抗菌活性，MIC值分别为16 µg/mL和32 µg/mL。部分化合物抗真菌活性与参考药物氟康唑相接近。
Claims (6)
1.1-氧代-2,8-二氮杂螺[4.5]癸烷L-酒石酸衍生物类及其制备方法和应用，其特征在于：该螺环化合物8-位通过L-酒石酸与一含氮的片断相连，组成如通式1所示结构的化合物：
。
2.如权利要求1所述，该类化合物中取代基为可为以基团：
其中R1为H；R2为Ph，4-ClC6H4，2-CH3OC6H4，2,4-ClC6H3，2-BrC6H4，4-FC6H4，2-CH3C6H4，3,5-CF3C6H3，4-CH3OC6H4，3,4-FC6H3，2-FC6H4，4-O2NC6H4，3-CF3C6H4，3-Cl-4-FC6H3，3-CH3OC6H4，4-BrC6H4，2- ClC6H4，2,4-FC6H3等。
3.如权利要求1所述化合物的合成方法，按Scheme 1所示进行
。
4.如权利要求3所示，步骤(a)中，溶剂为二氯甲烷、三氯甲烷、四氢呋喃、二氧六环等，优选二氯甲烷；化合物2，3a，的摩尔比为1: 1.1~2，室温至50℃，反应4-8 h。
5.如权利要求3所示，步骤(b)中，溶剂为二氯甲烷、三氯甲烷、四氢呋喃、二氧六环等，优选二氯甲烷；化合物5：4a摩尔比1: 1.1~2，优选二氯甲烷为溶剂，室温至50℃反应6-12h。
6.如权利要求2所述化合物在制备抗病原微生物药物中的应用，所述微生物为病原细菌或病原真菌，如大肠杆菌、金黄色葡萄球菌、耐甲氧西林金黄色葡萄球菌、枯草杆菌、变形杆菌、铜绿色假单胞菌；白色念珠菌、新型隐球菌、黄曲霉菌、烟曲霉菌等。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811537842.5A CN109400608B (zh) | 2018-12-15 | 2018-12-15 | 二氮杂螺[4，5]癸烷酒石酸类衍生物制备和应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811537842.5A CN109400608B (zh) | 2018-12-15 | 2018-12-15 | 二氮杂螺[4，5]癸烷酒石酸类衍生物制备和应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109400608A true CN109400608A (zh) | 2019-03-01 |
| CN109400608B CN109400608B (zh) | 2021-08-31 |
Family
ID=65459368
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811537842.5A Expired - Fee Related CN109400608B (zh) | 2018-12-15 | 2018-12-15 | 二氮杂螺[4，5]癸烷酒石酸类衍生物制备和应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109400608B (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116143782A (zh) * | 2021-11-22 | 2023-05-23 | 西南大学 | 一类螺[吡咯烷-2,3’-喹啉]-2‘-酮类衍生物的设计合成与应用 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101426486A (zh) * | 2005-12-01 | 2009-05-06 | 先灵公司 | 用于炎性疾病和微生物疾病治疗的化合物 |
| CN103003233A (zh) * | 2010-04-20 | 2013-03-27 | 大正制药株式会社 | 新型异羟肟酸衍生物 |
| CN103068826A (zh) * | 2010-08-13 | 2013-04-24 | 霍夫曼-拉罗奇有限公司 | 新型氮杂环化合物 |
| US20130245013A1 (en) * | 2004-08-14 | 2013-09-19 | Boehringer Ingelheim International Gmbh | Storage stable perfusion solution for dihydropteridinones |
-
2018
- 2018-12-15 CN CN201811537842.5A patent/CN109400608B/zh not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130245013A1 (en) * | 2004-08-14 | 2013-09-19 | Boehringer Ingelheim International Gmbh | Storage stable perfusion solution for dihydropteridinones |
| CN101426486A (zh) * | 2005-12-01 | 2009-05-06 | 先灵公司 | 用于炎性疾病和微生物疾病治疗的化合物 |
| CN103003233A (zh) * | 2010-04-20 | 2013-03-27 | 大正制药株式会社 | 新型异羟肟酸衍生物 |
| CN103068826A (zh) * | 2010-08-13 | 2013-04-24 | 霍夫曼-拉罗奇有限公司 | 新型氮杂环化合物 |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116143782A (zh) * | 2021-11-22 | 2023-05-23 | 西南大学 | 一类螺[吡咯烷-2,3’-喹啉]-2‘-酮类衍生物的设计合成与应用 |
| CN116143782B (zh) * | 2021-11-22 | 2024-04-12 | 西南大学 | 一类螺[吡咯烷-2,3'-喹啉]-2'-酮类衍生物的设计合成与应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109400608B (zh) | 2021-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhang et al. | Synthesis of novel sulfonamide azoles via C–N cleavage of sulfonamides by azole ring and relational antimicrobial study | |
| Wang et al. | Synthesis and biological activities of thio-triazole derivatives as novel potential antibacterial and antifungal agents | |
| US4794120A (en) | Antiparasitic nitrofuran derivatives | |
| US4843070A (en) | Substituted thiazetoquinoline-3-carboxylic acids and pharmaceutically acceptable salts thereof | |
| DK158346B (da) | Analogifremgangsmaade til fremstilling af 4-amino-5-alkylsulfonyl-o-anisamid-derivater samt 2-methoxy-4-amino-5-alkylsulfonylbenzoesyrer til anvendelse som mellemprodukter ved fremgangsmaaden | |
| ES2268011T3 (es) | Oxazolidinonas que contienen un grupo sulfonimida como antibioticos. | |
| HRP950408A2 (en) | 6-membered n-heteroaryloxazolidinones | |
| CN109608436A (zh) | 取代的甲基甲酰基试剂及使用所述试剂改进化合物物理化学和/或药代动力学性质的方法 | |
| V Shtyrlin et al. | Synthesis and antibacterial activity of novel quaternary ammonium pyridoxine derivatives | |
| US20030018023A1 (en) | 5-6 or 5-7 Heterobicycles as Factor Xa inhibitors | |
| JP2024528245A (ja) | 芳香族アセチレン系誘導体及びその製造方法と用途 | |
| CN113264949B (zh) | 一类螺苯并噁嗪哌啶α,β-不饱和酮类衍生物的设计合成与应用 | |
| CN110713459A (zh) | 一类喹啉酮富马来酰胺衍生物的设计合成与应用 | |
| CN109400608A (zh) | 二氮杂螺[4，5]癸烷酒石酸类衍生物制备和应用 | |
| CN109593089B (zh) | 二氮杂螺癸烷哌啶甲酰胺类化合物制备和应用 | |
| EP2991992B1 (en) | Quinolone derivatives | |
| US4044130A (en) | Compositions for the control of microorganisms | |
| JPH02292289A (ja) | 置換アゼチジニルイソチアゾロピリドン誘導体、その製造法及びその医薬用途 | |
| EP0431856A2 (en) | Heterocyclic compounds | |
| CN102796111A (zh) | 氧氮杂螺环酰胺基团的羧(磺)酸酯类化合物及制备方法和用途 | |
| SU1456015A3 (ru) | Способ получени производных 1,8-нафтиридина или их кислотно-аддитивных солей (его варианты) | |
| Shiba et al. | Uses of piperonal in the synthesis of novel prop-2-enoyl amides, esters, heterocyclic systems and study of their antibacterial activities | |
| Siddiqui et al. | Effects of skeletal modifications of ciprofloxacin on antibacterial, antifungal and cytotoxic activities | |
| CN112624962B (zh) | 一类具有双手性中心的咔唑基异丙醇胺衍生物及其制备方法和应用 | |
| CS157191A3 (en) | Pyrrido/3,4-b/pyrrolo/1,2-e//1,4,5/oxadiazepines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20210831 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |